Ovarian cancer is the most frequent cause of gynaecologic cancer-related mortality in
women. The overall 5-year survival of ovarian carcinoma is less than 30%, creating a
pressing need to understand its biology and develop effective and less toxic therapies
for ovarian cancer. Ovarian cancer is associated with a poor prognosis largely due to
the advanced stage of disease at the time of diagnosis.These advanced stage tumors
typically have peritoneal metastases along with ascites fluid accumulation rendering
them principally inoperable and unresponsive to current treatment options. Ovarian
carcinomas metastasize by attaching to and invading through the mesothelial lining
of the peritoneal cavity. A practical and effective screening program for early detection
of ovarian cancer would therefore be a helpful mean.The techniques currently available-
transvaginal ultrasound and CA125 (a biomarker of ovarian cancer) serum assays-are
problematic for a number of reasons. For example, CA125 is not consistently elevated
in serum from patients with early-stage disease and may be elevated in patients with
benign gynecologic diseases.Details........
L u b n a
Y a s m i n